依米康(300249.SZ):已成功完成浸沒式液冷產品的開發,並在中東地區成功投運首台套NetLiq200 2.0液冷升級版產品
格隆匯6月14日丨有投資者於投資者互動平台向依米康(300249.SZ)提問,“請問公司的液冷產品和哪些大廠的數據中心有合作?”,公司回覆稱,公司已成功完成浸沒式液冷產品的開發,並在中東地區成功投運首台套NetLiq200 2.0液冷升級版產品。此產品採用先進穩定的模塊化集裝箱方案,以整體模塊化思路,從服務器到冷源進行統籌設計,從供電、散熱到結構尺寸進行綜合考量,實現液冷系統數據中心的模塊化交付,以即插即用的連接方式,比傳統安裝節省50%的安裝時間。公司將持續關注液冷技術相關的技術應用和市場機會,將積極、努力拓展數字基礎設施的市場訂單。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.